Literature DB >> 9640364

Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity.

F Ameglio1, L D'Auria, C Bonifati, C Ferraro, A Mastroianni, B Giacalone.   

Abstract

Few and contrasting data are available in the literature concerning the levels of various cytokines in blister fluid (BF) and in the serum of patients affected with bullous pemphigoid (BP). Using commercially available ELISA kits, this study reports the levels of 11 cytokines detected both in BF and sera of 15 BP patients and compares them with those of 15 control subjects' sera. Generally, no significant differences were observed in BP and control sera. In contrast, interleukin (IL) 1 beta, IL-2, IL-4, IL-5, IL-6, IL-8, tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) showed increased BF levels as compared with BP sera. Two cytokines, IL-11 and IL-12 did not show significant differences between BP BF and sera, while an opposite behaviour was observed for transforming growth factor beta 1 (TGF-beta 1), whose serum levels were higher than the concentrations in BF. Using the number of lesions of the patients as a possible disease intensity marker, significant correlations were found with the BF levels of IL-1 beta, IL-8, TNF-alpha and, most closely, IL-5. These data may have pathogenetic relevance and suggest the possibility that these biological modulators may be used as a quantitative marker of disease intensity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640364     DOI: 10.1046/j.1365-2133.1998.02169.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  25 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 3.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 4.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2022-08-14       Impact factor: 6.233

6.  Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature.

Authors:  Amy Attaway; Tracey L Mersfelder; Sakshi Vaishnav; Joanne K Baker
Journal:  J Dermatol Case Rep       Date:  2014-03-31

7.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.

Authors:  A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

8.  TSST-1+Staphylococcus aureus in Bullous Pemphigoid.

Authors:  Kelly N Messingham; Michael P Cahill; Samuel H Kilgore; Ananya Munjal; Patrick M Schlievert; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2021-10-01       Impact factor: 7.590

9.  Serum levels of hypersensitive-C-reactive protein in moderate and severe acne.

Authors:  M R Namazi; A R Parhizkar; F Jowkar
Journal:  Indian Dermatol Online J       Date:  2015 Jul-Aug

10.  Detection of Anti-basement Membrane Zone Antibodies in the Blister Fluid in Subepidermal Autoimmune Bullous Diseases.

Authors:  Ravindran Surya; Bobbili Tejasvi; Shrutakirthi D Shenoi; Sathish Pai; Chythra Rao; Raghavendra Rao
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.